Profund Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Profund Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$372K	Buy	20,710 +3,558	+21%	+$55K	0.01%	687
2026 Q1	$238K	Sell	17,152 -3,437	-17%	-$48.3K	0.01%	917
2025 Q4	$249K	Buy	20,589 +7,171	+53%	+$97.4K	0.01%	1013
2025 Q3	$182K	Buy	+13,418	New	+$126K	0.01%	998
2024 Q2	–	Sell	-64,969	Closed	-$185K	–	1082
2024 Q1	$185K	Buy	64,969 +40,362	+164%	+$528K	0.01%	1087
2023 Q4	$362K	Buy	24,607 +5,239	+27%	+$80.3K	0.02%	682
2023 Q3	$355K	Buy	19,368 +5,558	+40%	+$118K	0.02%	582
2023 Q2	$298K	Buy	13,810 +871	+7%	+$23.5K	0.02%	725
2023 Q1	$380K	Buy	+12,939	New	+$450K	0.02%	614

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Profund Advisors's AMLX Position: Q2 2026 in Review

Profund Advisors increased its Amylyx Pharmaceuticals (AMLX) stake by 21% in Q2 2026, buying an estimated $55K and bringing the position to 20,710 shares worth $372K. The position accounts for 0.01% of the portfolio, ranked #687.

Profund Advisors first reported a position in AMLX in Q1 2023 and has held it in 9 quarters since. The position peaked at $380K in Q1 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Profund Advisors held 20,710 shares of Amylyx Pharmaceuticals worth $372K as of Q2 2026.
Profund Advisors bought 3,558 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $55K.
Amylyx Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #687 holding.
Profund Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 9 quarters since.
Profund Advisors's Amylyx Pharmaceuticals position peaked at $380K in Q1 2023.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.